Key regions: India, China, Japan, Canada, South Korea
The Sensory Organ Drugs market in Eastern Asia has been experiencing significant growth in recent years.
Customer preferences: Customers in Eastern Asia have been increasingly interested in sensory organ drugs due to the rising prevalence of sensory organ disorders such as age-related macular degeneration, glaucoma, and cataracts. Additionally, the region's aging population has also contributed to the growing demand for these drugs.
Trends in the market: China, Japan, and South Korea are the largest markets for sensory organ drugs in Eastern Asia. In China, the government's increased focus on healthcare and the implementation of policies to address the country's aging population have driven the growth of the market. Japan has a highly developed healthcare system and a large elderly population, which has led to a high demand for sensory organ drugs. In South Korea, the market has been driven by the country's rapidly aging population and the increasing prevalence of eye diseases.
Local special circumstances: In China, the government's focus on healthcare has led to the implementation of policies that aim to increase access to healthcare services and reduce the cost of drugs. This has created opportunities for both domestic and foreign pharmaceutical companies to enter the market. In Japan, the highly developed healthcare system has led to a competitive market, with many domestic and foreign companies vying for market share. In South Korea, the market is dominated by domestic companies, with international companies facing significant barriers to entry.
Underlying macroeconomic factors: The growing demand for sensory organ drugs in Eastern Asia can be attributed to the region's aging population and the increasing prevalence of eye diseases. Additionally, the implementation of policies aimed at improving healthcare access and reducing drug costs has also contributed to the growth of the market. However, the market is also facing challenges such as regulatory hurdles, high development costs, and competition from generic drugs. As such, companies operating in the market must develop innovative drugs and strategies to remain competitive.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
